Literature DB >> 28898125

JOURNAL CLUB: Diagnostic Utility of MRI After Negative or Inconclusive Mammography for the Evaluation of Pathologic Nipple Discharge.

Manisha Bahl1, Michele A Gadd2, Constance D Lehman1.   

Abstract

OBJECTIVE: The purpose of this study is to determine the diagnostic utility of MRI after negative or inconclusive mammography for the evaluation of pathologic nipple discharge.
MATERIALS AND METHODS: We conducted a retrospective review of breast MRI examinations from January 1, 2006, through December 31, 2015, that were performed after negative or inconclusive mammography for the evaluation of nipple discharge. Clinical notes, imaging findings, and pathology outcomes were reviewed.
RESULTS: One hundred eighteen women (mean age, 49 years; range, 23-82 years) underwent MRI for evaluation of nipple discharge, 105 (89.0%) of whom had surgical excision or at least 2-year imaging follow-up. A total of six patients (6/105; 5.7%) were diagnosed with malignancy (ductal carcinoma in situ [DCIS] or invasive malignancy). Of 27 patients with positive MRI findings (final assessment of BI-RADS category 4), three (11.1%) were diagnosed with malignancy: DCIS grade 2-3, DCIS with focus of microinvasive ductal carcinoma, and invasive papillary carcinoma. An additional three patients (without suspicious findings at MRI) were diagnosed with malignancy at surgical excision, all of which were grade 1 DCIS. For patients with negative MRI findings (BI-RADS category 1, 2, or 3), the negative predictive value of MRI for malignancy was 96.2% (75/78).
CONCLUSION: In women with nipple discharge and negative or inconclusive mammography findings, the risk of malignancy is low, at 5.7%. With negative MRI findings (BI-RADS category 1, 2, or 3), the risk of malignancy is less than 4%. Surveillance rather than surgical excision may be a reasonable option for patients without suspicious findings at MRI.

Entities:  

Keywords:  MRI; breast; nipple discharge

Mesh:

Year:  2017        PMID: 28898125     DOI: 10.2214/AJR.17.18139

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  7 in total

1.  Predicting Patients Found to Have Malignancy at Nipple Duct Surgery.

Authors:  Nour Alshurbasi; Christopher W J Cartlidge; Stanley R Kohlhardt; Sirwan M Hadad
Journal:  Breast Care (Basel)       Date:  2019-12-13       Impact factor: 2.860

2.  Stereotaxic Core-Needle Biopsy in Assessing Intraductal Pathologic Findings at Ductography.

Authors:  G A Belonenko; N A Sukhina; A A Aksyonov; E G Aksyonova
Journal:  Eur J Breast Health       Date:  2022-07-01

3.  Feasibility of Narrow-Band Imaging, Intraductal Biopsy, and Laser Ablation During Mammary Ductoscopy: Protocol for an Interventional Study.

Authors:  S Makineli; M D Filipe; F Euwe; A Sakes; J Dankelman; P Breedveld; M R Vriens; P J van Diest; A J Witkamp
Journal:  Int J Surg Protoc       Date:  2022-09-01

4.  The Value of Adding Ductography to Ultrasonography for the Evaluation of Pathologic Nipple Discharge in Women with Negative Mammography.

Authors:  Younjung Choi; Sun Mi Kim; Mijung Jang; Bo La Yun; Eunyoung Kang; Eun-Kyu Kim; So Yeon Park; Bohyoung Kim; Nariya Cho; Woo Kyung Moon
Journal:  Korean J Radiol       Date:  2022-09       Impact factor: 7.109

5.  DBT-galactography: a promising tool for improving the diagnostic workup of nipple discharge.

Authors:  Marco Moschetta; Vincenzo De Ruvo; Angelica Drago; Nicoletta Troiano; Simona Paolicelli; Giuseppe Rubini; Amato Antonio Stabile Ianora; Michele Telegrafo
Journal:  Eur Radiol Exp       Date:  2020-08-04

Review 6.  Nipple discharge: The state of the art.

Authors:  Giovanna Panzironi; Federica Pediconi; Francesco Sardanelli
Journal:  BJR Open       Date:  2018-11-07

Review 7.  Meta-analysis and cost-effectiveness of ductoscopy, duct excision surgery and MRI for the diagnosis and treatment of patients with pathological nipple discharge.

Authors:  M D Filipe; S I S Patuleia; M R Vriens; P J van Diest; A J Witkamp
Journal:  Breast Cancer Res Treat       Date:  2021-01-21       Impact factor: 4.872

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.